Table 1.
Study | Country | N | Age (y) | Gender (Male) | Cancer site | Treatment | Outcomes |
---|---|---|---|---|---|---|---|
Liang et al. [14] | China | 18 | 63.1 ± 12.1 | 12 (66.6) | 5 lung, 3 breast, 2 bladder, 4 colon/colorectal, other cancers | Most patients were in the postoperative period of tumor resection, while few were still undergoing chemo/targeted therapy | Severe events occurred in 9/18 patients |
He et al. [4] | China | 13 | 35 (23–53) | 7.00 | All hematological malignancy (M/C acute lymphoblastic AND myeloid leukemias) | 6 patients received chemotherapy, 3 received allotransplant, among other modalities | 4 moderate, 4 severe, and 5 critical |
Martín-Moro et al. [17] | Spain | 34 | 72.5 (35–94) | 19 (55.9) | 7 acute leukemia, 1 plasma cell dyscrasia, 6 CLL, 5 NHL, among others (most patients were in remission) | 16 patients were receiving treatment at the time of COVID diagnosis and 3 patients received most recent TTT 6 months before COVID diagnosis | 17 patients developed moderate/severe ARDS, 4 mechanical ventilation, and 2 ICU admission |
Miyashita et al. [3] | USA | 334 | Most patients (50–80) | NA | 57, 56, 23, 18, and 16 patients with breast, prostate, lung, urothelial, and colon cancer, respectively | NA | Cancer patients had higher risk of intubation than non-cancer patients, while the death rate was similar |
Zhang et al. [27] | China | 28 | 65 (56–70) | 17 (60.7) | Most common were lung (7), esophagus (4), and breast (3) | Most patients underwent operations 21 (75%) or chemo/radiotherapy 25 (89.3%) | 8 patients died, 8 developed ARDS, 6 ICU admission, and 15 had severe events |
Mehta et al. [18] | USA | 218 | 76 (10–92) | 117.00 | 54 hematologic malignancies and 164 solid malignancies; metastasis (42) and active cancer (92) | Most patients were on active chemotherapy/radiotherapy and few were on targeted immunotherapy | 61 patients died, 23 ICU admission, and 45 mechanical ventilation |
Yang et al. [25] | China | 52 | 63 (34–98) | 28.00 | Lung cancer (19.2%), breast cancer (17.3%), rectal cancer (15.4%), colon cancer (9.6%), cervical cancer (7.7%), and thyroid carcinoma (5.8%) | 33 mild cases and 19 severe/critical cases (11 died) | |
Guan et al. [2] | China | 18 | 63.1 ± 12.1 | 11 (61.1) | NA | NA | 9 severe cases, 3 died, 5 ICU admissions, 2 mechanical ventilation |
Yu et al. [26] | China | 12 | Most patients > 60 | 10.00 | 7 lung cancer, 3 gastrointestinal cancers, 1 breast cancer, and 1 urothelial cancer | Most patients were receiving radiochemotherapy; three patients were receiving best supportive care only | 3 patients died and 6 were discharged alive |
Ma et al. [16] | China | 37 | 62 (59–70) | 20 (54.1) | 11 colorectal cancer, 8 lung cancer, 7 breast cancer, and 5 gynecological cancer | 13 had received antitumor therapy within 1 month of diagnosis | 20 severe/critical cases, of which 5 died |
Dai et al. [12] | China | 105 | 64 (IQR: 14) | 57 (54.72) | 22 lung cancer , 13 gastrointestinal cancer, 11 breast cancer, 11 thyroid cancer, and 9 hematologic cancer | 12 died, 20 ICU admission, and 10 mechanical ventilation |
Note. ARDS = acute respiratory distress syndrome; CLL = chronic lymphocytic leukemia; ICU = intensive care unit; IQR = interquartile range; NA = not available; NHL = non-Hodgkin lymphoma.